Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 553

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

GABAergic dysfunction in mood disorders

Brambilla, P, Perez, J, Barale, F, Schettini, G, Soares, J C·2003·Molecular Psychiatry
DOI 10.1038/sj.mp.4001362
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001362

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 277

  1. Zachmann M, Tocci P, Nyhan WL . The occurrence of gamma-aminobutyric acid in human tissues other than brain. J Biol Chem 1966; 241: 1355–1358. · DOI
  2. Otsuka M, Iversen LL, Hall ZW, Kravitz EA . Release of gamma-aminobutyric acid from inhibitory nerves of lobster. Proc Natl Acad Sci USA 1966; 56: 1110–1115. · DOI · Paper page
  3. Meldrum B . Pharmacology of GABA. Clin Neuropharmacol 1982; 5: 293–316. · DOI
  4. Guidotti A, Corda MG, Wise BC, Vaccarino F, Costa E . GABAergic synapses. Supramolecular organization and biochemical regulation. Neuropharmacology 1983; 22: 1471–1479. · DOI
  5. Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A . Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Archiv Psychiatrie Nervenkrankheiten 1980; 229: 1–16. · DOI
  6. Massat I, Sourey D, Papadimitriou GN, Mendlewicz J . The GABAergic hypothesis of mood disorders. In: Soares JC, Gershon S (eds). Bipolar Disorders, Basic Mechanisms and Therapeutic Implication. Marcel Dekker: New York, 2000, pp. 143–165.
  7. Peng L, Hertz L, Huang R, Sonnewald U, Petersen SB, Westergaard N et al. Utilization of glutamine and of TCA cycle constituents as precursors for transmitter glutamate and GABA. Dev Neurosci 1993; 15: 367–377. · DOI
  8. Schousboe A, Westergaard N, Sonnewald U, Petersen SB, Huang R, Peng L et al. Glutamate and glutamine metabolism and compartmentation in astrocytes. Dev Neurosci 1993; 15: 359–366. · DOI
  9. Durkin MM, Smith KE, Borden LA, Weinshank RL, Branchek TA, Gustafson EL . Localization of messenger RNAs encoding three GABA transporters in rat brain: an in situ hybridization study. Brain Res Mol Brain Res 1995; 33: 7–21. · DOI
  10. Borden LA . GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 1996; 29: 335–356. · DOI · Paper page
  11. Cherubini E, Conti F . Generating diversity at GABAergic synapses. Trends Neurosci 2001; 24: 155–162. · DOI
  12. Eder M, Rammes G, Zieglgansberger W, Dodt H-U . GABAA and GABAB receptors on neocortical neurons are differentialy distributed. Eur J Neurosci 2001; 13: 1065–1069. · DOI
  13. Costa E, Auta J, Grayson DR, Matsumoto K, Pappas GD, Zhang X et al. GABAA receptors and benzodiapines: a role for dendritic resident subunit mRNAs. Neuropharmacology 2002; 43: 925–937. · DOI
  14. Bormann J . Electrophysiology of GABAA and GABAB receptor subtypes. Trends Neurosci 1988; 11: 112–116. · DOI
  15. Macdonald RL, Twyman RE, Ryan-Jastrow T, Angelotti TP . Regulation of GABAA receptor channels by anticonvulsant and convulsant drugs and by phosphorylation. Epilepsy Res Suppl 1992; 9: 265–277.
  16. Haefely W, Kulcsar A, Mohler H . Possible involvement of GABA in the central actions of benzodiazepines. Psychopharmacol Bull 1975; 11: 58–59.
  17. Nicoll RA, Eccles JC, Oshima T, Rubia F . Prolongation of hippocampal inhibitory postsynaptic potentials by barbiturates. Nature 1975; 258: 625–627. · DOI · Paper page
  18. Narahashi T, Arakawa O, Brunner EA, Nakahiro M, Nishio M, Ogata N et al. Modulation of GABA receptor-channel complex by alcohols and general anesthetics. Adv Biochem Psychopharmacol 1992; 47: 325–334.
  19. Mhatre M, Ticku MK . Chronic ethanol treatment upregulates the GABA receptor beta subunit expression. Brain Res Mol Brain Res 1994; 23: 246–252. · DOI
  20. Curtis DR, Duggan AW, Felix D, Johnston GA . Bicuculline and central GABA receptors. Nature 1970; 228: 676–677. · DOI
  21. Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M et al. International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol Rev 2002; 54: 247–264. · DOI · Paper page
  22. Karbon EW, Duman RS, Enna SJ . GABAB receptors and norepinephrine-stimulated cAMP production in rat brain cortex. Brain Res 1984; 306: 327–332. · DOI
  23. Pycock CJ, Horton RW . Dopamine-dependent hyperactivity in the rat following manipulation of GABA mechanisms in the region of the nucleus accumbens. J Neural Transm 1979; 45: 17–33. · DOI
  24. Jones MW, Kilpatrick IC, Phillipson OT . Dopamine function in the prefrontal cortex of the rat is sensitive to a reduction of tonic GABA-mediated inhibition in the thalamic mediodorsal nucleus. Exp Brain Res 1988; 69: 623–634. · DOI
  25. Reid M, Herrera-Marschitz M, Hokfelt T, Terenius L, Ungerstedt U . Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P. Eur J Pharmacol 1988; 147: 411–420. · DOI
  26. Benes FM, Vincent SL, Molloy R . Dopamine-immunoreactive axon varicosities form nonrandom contacts with GABA-immunoreactive neurons of rat medial prefrontal cortex. Synapse 1993; 15: 285–295. · DOI
  27. Dewey SL, Smith GS, Logan J, Brodie JD, Yu DW, Ferrieri RA et al. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci 1992; 12: 3773–3780. · DOI
  28. Schiffer WK, Gerasimov MR, Bermel RA, Brodie JD, Dewey SL . Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study. Life Sci 2000; 66: L169–L173. · DOI
  29. Ring HA, Trimble MR, Costa DC, George MS, Verhoeff P, Ell PJ . Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems. J Neurol Neurosurg Psychiatry 1992; 55: 758–761. · DOI
  30. Garbutt JC, van Kammen DP . The interaction between GABA and dopamine: implications for schizophrenia. Schizophr Bull 1983; 9: 336–353. · DOI
  31. Evangelista S, Borsini F, Meli A . Evidence that muscimol acts in the forced swimming test by activating the rat dopaminergic system. Life Sci 1987; 41: 2679–2684. · DOI
  32. Bonanno G, Raiteri M . Coexistence of carriers for dopamine and GABA uptake on a same nerve terminal in the rat brain. Br J Pharmacol 1987; 91: 237–243. · DOI
  33. Retaux S, Besson MJ, Penit-Soria J . Opposing effects of dopamine D2 receptor stimulation on the spontaneous and the electrically evoked release of [3H]GABA on rat prefrontal cortex slices. Neuroscience 1991; 42: 61–71. · DOI
  34. Floran B, Floran L, Sierra A, Aceves J . D2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus. Neurosci Lett 1997; 237: 1–4. · DOI
  35. Grobin AC, Deutch AY . Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat. J Pharmacol Exp Ther 1998; 285: 350–357.
  36. Harsing Jr LG, Zigmond MJ . Influence of dopamine on GABA release in striatum: evidence for D1−D2 interactions and non-synaptic influences. Neuroscience 1997; 77: 419–429. · DOI
  37. Wang X, Zhong P, Yan Z . Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. J Neurosci 2002; 22: 9185–9193. · DOI · Paper page
  38. Cobb WS, Abercrombie ED . Distinct roles for nigral GABA and glutamate receptors in the regulation of dendritic dopamine release under normal conditions and in response to systemic haloperidol. J Neurosci 2002; 22: 1407–1413. · DOI
  39. Biswas B, Carlsson A . The effect of intracerebroventricularly administered GABA on brain monoamine metabolism. Naunyn Schmiedebergs Arch Pharmacol 1977; 299: 41–46. · DOI
  40. Biswas B, Carlsson A . The effect of intraperitoneally administered GABA on brain monoamine metabolism. Naunyn Schmiedebergs Arch Pharmacol 1977; 299: 47–51. · DOI
  41. Scatton B, Zivkovic B, Dedek J, Lloyd KG, Constantinidis J, Tissot R et al. Gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J Pharmacol Exp Ther 1982; 220: 678–688.
  42. Scatton B, Lloyd KG, Zivkovic B, Dennis T, Claustre Y, Dedek J et al. Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat. J Pharmacol Exp Ther 1987; 241: 251–257.
  43. Suzdak PD, Gianutsos G . Differential coupling of GABA-A and GABA-B receptors to the noradrenergic system. J Neural Transm 1985; 62: 77–89. · DOI
  44. Bonanno G, Raiteri M . Carriers for GABA and noradrenaline uptake coexist on the same nerve terminal in rat hippocampus. Eur J Pharmacol 1987; 136: 303–310. · DOI
  45. Bonanno G, Raiteri M . Release-regulating GABAA receptors are present on noradrenergic nerve terminals in selective areas of the rat brain. Synapse 1987; 1: 254–257. · DOI
  46. Suzdak PD, Gianutsos G . Parallel changes in the sensitivity of gamma-aminobutyric acid and noradrenergic receptors following chronic administration of antidepressant and GABAergic drugs. A possible role in affective disorders. Neuropharmacology 1985; 24: 217–222. · DOI
  47. Ferraro L, Tanganelli S, Calo G, Antonelli T, Fabrizi A, Acciarri N et al. Noradrenergic modulation of gamma-aminobutyric acid outflow from the human cerebral cortex. Brain Res 1993; 629: 103–108. · DOI
  48. Mitoma H, Konishi S . Monoaminergic long-term facilitation of GABA-mediated inhibitory transmission at cerebellar synapses. Neuroscience 1999; 88: 871–883. · DOI
  49. Nishikawa T, Scatton B . Evidence for a GABAergic inhibitory influence on serotonergic neurons originating from the dorsal raphe. Brain Res 1983; 279: 325–329. · DOI
  50. Nishikawa T, Tanaka M, Tsuda A, Kohno Y, Nagasaki N . Serotonergic−catecholaminergic interactions and foot shock-induced jumping behavior in rats. Eur J Pharmacol 1983; 94: 53–58. · DOI
  51. Nishikawa T, Scatton B . Inhibitory influence of GABA on central serotonergic transmission. Raphe nuclei as the neuroanatomical site of the GABAergic inhibition of cerebral serotonergic neurons. Brain Res 1985; 331: 91–103. · DOI
  52. Francois-Bellan AM, Hery M, Faldon M, Hery F . Evidence for GABA on serotonin metabolism in the rat suprachiasmatic area. Neurochem Int 1988; 134: 455–462. · DOI
  53. Bagdy E, Kiraly I, Harsing LG . Reciprocal innervation between serotonergic and GABAergic neurons in raphe nuclei of the rat. Neurochem Res 2000; 25: 1465–1473. · DOI
  54. Shen RY, Andrade R . 5-Hydroxytryptamine2 receptor facilitates GABAergic neurotransmission in rat hippocampus. J Pharmacol Exp Ther 1998; 285: 805–812.
  55. Abi-Saab WM, Bubser M, Roth RH, Deutch AY . 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 1999; 20: 92–96. · DOI
  56. Liu R, Jolas T, Aghajanian G . Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res 2000; 873: 34–45. · DOI
  57. Green AR, Johnson P, Mountford JA, Nimgaonkar VL . Some anticonvulsant drugs alter monoamine-mediated behaviour in mice in ways similar to electroconvulsive shock; implications for antidepressant therapy. Br J Pharmacol 1985; 84: 337–346. · DOI
  58. Metz A, Goodwin GM, Green AR . The administration of baclofen to mice increases 5-HT2-mediated head-twitch behaviour and 5-HT2 receptor number in frontal cortex. Neuropharmacology 1985; 24: 357–360. · DOI
  59. Gray JA, Metz A, Goodwin GM, Green AR . The effects of the GABA-mimetic drugs, progabide and baclofen, on the biochemistry and function of 5-hydroxytryptamine and noradrenaline. Neuropharmacology 1986; 25: 711–716. · DOI
  60. Sibille E, Pavlides C, Benke D, Toth M . Genetic inactivation of the Serotonin(1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety. J Neurosci 2000; 20: 2758–2765. · DOI
  61. Maggi A, Perez J . Role of female gonadal hormones in the CNS: clinical and experimental aspects. Life Sci 1985; 37: 893–906. · DOI
  62. Perez J, Zucchi A, Maggi A . Sexual dimorphism in the response of the GABAergic system to estrogen administration. J Neurochem 1986; 47: 1798–1803. · DOI
  63. McEwen BS . Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 1991; 12: 141–147. · DOI · Paper page
  64. van Broekhoven F, Verkes RJ . Neurosteroids in depression: a review. Psychopharmacology 2003; 165: 97–110. · DOI
  65. Do-Rego JL, Mensah-Nyagan GA, Beaujean D, Vaudry D, Sieghart W, Luu-The V et al. Gamma-Aminobutyric acid, acting through gamma-aminobutyric acid type A receptors, inhibits the biosynthesis of neurosteroids in the frog hypothalamus. Proc Natl Acad Sci USA 2000; 97: 13925–13930. · DOI
  66. Haage D, Druzin M, Johansson S . Allopregnanolone modulates spontaneous GABA release via presynaptic Cl− permeability in rat preoptic nerve terminals. Brain Res 2002; 958: 405–413. · DOI
  67. McIntyre KL, Porter DM, Henderson LP . Anabolic androgenic steroids induce age-, sex-, and dose-dependent changes in GABAA receptor subunit mRNAs in the mouse forebrain. Neuropharmacology 2002; 43: 634–645. · DOI
  68. Mancinelli A, D'Aranno V, Borsini F, Meli A . Lack of relationship between effect of desipramine on forced swimming test and brain levels of desipramine or its demethylated metabolite in rats. Psychopharmacology 1987; 92: 441–443. · DOI
  69. Borsini F, Mancinelli A, D'Aranno V, Evangelista S, Meli A . On the role of endogenous GABA in the forced swimming test in rats. Pharmacol Biochem Behav 1987; 29: 275–279. · DOI
  70. Poncelet M, Martin P, Danti S, Simon P, Soubrie P . Noradrenergic rather than GABAergic processes as the common mediation of the antidepressant profile of GABA agonists and imipraminelike drugs in animals. Pharmacol Biochem Behav 1987; 28: 321–326. · DOI
  71. Sherman AD, Petty F . Neurochemical basis of the action of antidepressants on learned helplessness. Behav Neural Biol 1980; 30: 119–134. · DOI · Paper page
  72. Petty F, Sherman AD . GABAergic modulation of learned helplessness. Pharmacol Biochem Behav 1981; 15: 567–570. · DOI
  73. Sherman AD, Petty F . Additivity of neurochemical changes in learned helplessness and imipramine. Behav Neural Biol 1982; 35: 344–353. · DOI
  74. Lloyd KG, Morselli PL, Depoortere H, Fournier V, Zivkovic B, Scatton B et al. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav 1983; 18: 957–966. · DOI
  75. Drugan RC, Morrow AL, Weizman R, Weizman A, Deutsch SI, Crawley JN et al. Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Res 1989; 487: 45–51. · DOI
  76. Nakagawa Y, Ishima T, Ishibashi Y, Tsuji M, Takashima T . Involvement of GABAB receptor systems in experimental depression: baclofen but not bicuculline exacerbates helplessness in rats. Brain Res 1996; 741: 240–245. · DOI
  77. Nakagawa Y, Ishima T, Ishibashi Y, Tsuji M, Takashima T . Involvement of GABAB receptor systems in action of antidepressants. II: Baclofen attenuates the effect of desipramine whereas muscimol has no effect in learned helplessness paradigm in rats. Brain Res 1996; 728: 225–230. · DOI
  78. Martin P, Pichat P, Massol J, Soubrie P, Lloyd KG, Puech AJ . Decreased GABA B receptors in helpless rats: reversal by tricyclic antidepressants. Neuropsychobiology 1989; 22: 220–224. · DOI
  79. Plaznik A, Tamborska E, Hauptmann M, Bidzinski A, Kostowski W . Brain neurotransmitter systems mediating behavioral deficits produced by inescapable shock treatment in rats. Brain Res 1988; 447: 122–132. · DOI
  80. Corda MG, Blaker WD, Mendelson WB, Guidotti A, Costa E . beta-Carbolines enhance shock-induced suppression of drinking in rats. Proc Natl Acad Sci USA 1983; 80: 2072–2076. · DOI
  81. Drugan RC, Maier SF, Skolnick P, Paul SM, Crawley JN . An anxiogenic benzodiazepine receptor ligand induces learned helplessness. Eur J Pharmacol 1985; 113: 453–457. · DOI
  82. Guidotti A, Ferrero P, Costa E . On the brain endocoid for benzodiazepine recognition sites. Prog Clin Biol Res 1985; 192: 477–484.
  83. Kelly JP, Wrynn AS, Leonard BE . The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997; 74: 299–316. · DOI · Paper page
  84. Jancsar SM, Leonard BE . Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 263–269. · DOI
  85. Lloyd KG, Pichat P . Decrease in GABAB binding to the frontal cortex of olfactory bulbectomized rats. Br J Pharmacol 1986; 87: 36.
  86. Dennis T, Beauchemin V, Lavoie N . Differential effects of olfactory bulbectomy on GABAA and GABAB receptors in the rat brain. Pharmacol Biochem Behav 1993; 46: 77–82. · DOI
  87. Joly D, Lloyd KG, Pichat P, Sanger DJ . Correlation between the behavioral effect of desipramine and GABAB receptor regulation in the olfactory bulbectomized rat. Br J Pharmacol 1987; 90: 125.
  88. Leonard BE, Tuite M . Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 1981; 22: 251–286. · DOI
  89. Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G . Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther 1987; 241: 245–250.
  90. Grove J, Schechter PJ, Hanke NF, de Smet Y, Agid Y, Tell G et al. Concentration gradients of free and total gamma-aminobutyric acid and homocarnosine in human CSF: comparison of suboccipital and lumbar sampling. J Neurochem 1982; 39: 1618–1622. · DOI
  91. Loscher W . Relationship between GABA concentrations in cerebrospinal fluid and seizure excitability. J Neurochem 1982; 38: 293–295. · DOI
  92. Gold BI, Bowers Jr MB, Roth RH, Sweeney DW . GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry 1980; 137: 362–364. · DOI · Paper page
  93. Kasa K, Otsuki S, Yamamoto M, Sato M, Kuroda H, Ogawa N . Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry 1982; 17: 877–883.
  94. Berrettini WH, Nurnberger Jr JI, Hare TA, Simmons-Alling S, Gershon ES, Post RM . reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate. Biol Psychiatry 1983; 18: 185–194.
  95. Gerner RH, Hare TA . CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry 1981; 138: 1098–1101. · DOI
  96. Gerner RH, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M et al. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry 1984; 141: 1533–1540. · DOI
  97. Post RM, Ballenger JC, Hare TA, Goodwin FK, Lake CR, Jimerson DC et al. Cerebrospinal fluid GABA in normals and patients with affective disorders. Brain Res Bull 1980; 5 (Suppl 2): 755–759. · DOI
  98. Berrettini WH, Nurnberger Jr JI, Hare TA, Simmons-Alling S, Gershon ES . CSF GABA in euthymic manic-depressive patients and controls. Biol Psychiatry 1986; 21: 844–846. · DOI
  99. Joffe R, Post R, Rubinow D, Berrettini W, Hare T, Ballenger J et al. Cerebrospinal fluid GABA in manic-depressive illness. In: Bartholini G, Lloyd K, Morselli P (eds). GABA and Mood Disorders: Experimental and Clinical Research. Raven Press: New York, 1986.
  100. Petty F, Kramer G, Feldman M . Is plasma GABA of peripheral origin? Biol Psychiatry 1987; 22: 725–732. · DOI
  101. Petty F . Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? Clin Chem 1994; 40: 296–302. · DOI
  102. Ferkany JW, Smith LA, Seifert WE, Caprioli RM, Enna SJ . Measurement of gamma-aminobutyric acid (GABA) in blood. Life Sci 1978; 22: 2121–2128. · DOI
  103. Bohlen P, Huot S, Palfreyman MG . The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res 1979; 167: 297–305. · DOI
  104. Ferkany JW, Butler IJ, Enna SJ . Effect of drugs on rat brain, cerebrospinal fluid and blood GABA content. J Neurochem 1979; 33: 29–33. · DOI
  105. Loscher W . GABA in plasma and cerebrospinal fluid of different species. Effects of gamma-acetylenic GABA, gamma-vinyl GABA and sodium valproate. J Neurochem 1979; 32: 1587–1591. · DOI
  106. Apud JA, Racagni G, Iuliano E, Cocchi D, Casanueva F, Muller EE . Role of central nervous system-derived or circulating gamma-aminobutyric acid on prolactin secretion in the rat. Endocrinology 1981; 108: 1505–1510. · DOI
  107. Loscher W, Frey HH . Transport of GABA at the blood−CSF interface. J Neurochem 1982; 38: 1072–1079. · DOI
  108. Uhlhaas S, Lange H, Wappenschmidt J, Olek K . Free and conjugated CSF and plasma GABA in Huntington's chorea. Acta Neurol Scand 1986; 74: 261–265. · DOI
  109. Loscher W, Rating D, Siemes H . GABA in cerebrospinal fluid of children with febrile convulsions. Epilepsia 1981; 22: 697–702. · DOI
  110. Schmidt D, Loscher W . Plasma and cerebrospinal fluid gamma-aminobutyric acid in neurological disorders. J Neurol Neurosurg Psychiatry 1982; 45: 931–935. · DOI
  111. Berrettini WH, Nurnberger Jr JI, Hare T, Gershon ES, Post RM . Plasma and CSF GABA in affective illness. Br J Psychiatry 1982; 141: 483–487. · DOI
  112. Petty F, Schlesser MA . Plasma GABA in affective illness. A preliminary investigation. J Affect Disord 1981; 3: 339–343. · DOI
  113. Petty F, Sherman AD . Plasma GABA levels in psychiatric illness. J Affect Disord 1984; 6: 131–138. · DOI
  114. Petty F, Kramer GL, Dunnam D, Rush AJ . Plasma GABA in mood disorders. Psychopharmacol Bull 1990; 26: 157–161.
  115. Petty F, Kramer GL, Gullion CM, Rush AJ . Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol Psychiatry 1992; 32: 354–363. · DOI
  116. Petty F, Kramer GL, Fulton M, Moeller FG, Rush AJ . Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacol 1993; 9: 125–132. · DOI
  117. Petty F, Steinberg J, Kramer GL, Fulton M, Moeller FG . Desipramine does not alter plasma GABA in patients with major depression. J Affect Disord 1993; 29: 53–56. · DOI
  118. Petty F, Kramer GL, Fulton M, Davis L, Rush AJ . Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biol Psychiatry 1995; 37: 806–810. · DOI
  119. Prosser J, Hughes CW, Sheikha S, Kowatch RA, Kramer GL, Rosenbarger N et al. Plasma GABA in children and adolescents with mood, behavior, and comorbid mood and behavior disorders: a preliminary study. J Child Adolesc Psychopharmacol 1997; 7: 181–199. · DOI
  120. Petty F, Kramer G . Stability of plasma gamma-aminobutyric acid with time in healthy controls. Biol Psychiatry 1992; 31: 743–745. · DOI
  121. Schulz P, Lustenberger S, Degli Agosti R, Rivest RW . Plasma concentration of nine hormones and neurotransmitters during usual activities or constant bed rest for 34 H. Chronobiol Int 1994; 11: 367–380. · DOI
  122. Schulz P, Lloyd KG, Voltz C, Lustenberger S, Agosti RD . The plasma concentration of GABA shows no evidence of a circadian rhythm and is stable over weeks in normal males. Biol Rhythm Res 1994; 25: 291–300. · DOI
  123. Berrettini WH, Umberkoman-Wiita B, Nurnberger Jr. JI, Vogel WH, Gershon ES, Post RM . Platelet GABA-transaminase in affective illness. Psychiatry Res 1982; 7: 255–260. · DOI
  124. Kaiya H, Namba M, Yoshida H, Nakamura S . Plasma glutamate decarboxylase activity in neuropsychiatry. Psychiatry Res 1982; 6: 335–343. · DOI
  125. Nurnberger Jr. JI, Berrettini WH, Simmons-Alling S, Guroff JJ, Gershon ES . Intravenous GABA administration is anxiogenic in man. Psychiatry Res 1986; 19: 113–117. · DOI
  126. Devanand DP, Shapira B, Petty F, Kramer G, Fitzsimons L, Lerer B et al. Effects of electroconvulsive therapy on plasma GABA. Convuls Ther 1995; 11: 3–13.
  127. Petty F, Rush AJ, Davis JM, Calabrese JR, Kimmel SE, Kramer GL et al. Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry 1996; 39: 278–284. · DOI
  128. Rode A, Bidzinski A, Puzynski S . GABA levels in the plasma of patients with endogenous depression and during the treatment with thymoleptics. Psychiatr Pol 1991; 25: 4–7.
  129. Petty F, Fulton M, Moeller FG, Kramer G, Wilson L, Fraser K et al. Plasma gamma-aminobutyric acid (GABA) is low in alcoholics. Psychopharmacol Bull 1993; 29: 277–281.
  130. Yonkers KA . The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997; 58 (Suppl 15): 19–25.
  131. Roy A, DeJong J, Lamparski D, George T, Linnoila M . Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry 1991; 48: 428–432. · DOI
  132. Goddard AW, Narayan M, Woods SW, Germine M, Kramer GL, Davis LL et al. Plasma levels of gamma-aminobutyric acid and panic disorder. Psychiatry Res 1996; 63: 223–225. · DOI
  133. Gerner RH, Cohen DJ, Fairbanks L, Anderson GM, Young JG, Scheinin M et al. CSF neurochemistry of women with anorexia nervosa and normal women. Am J Psychiatry 1984; 141: 1441–1444. · DOI
  134. Bjork JM, Moeller FG, Kramer GL, Kram M, Suris A, Rush AJ et al. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 2001; 101: 131–136. · DOI
  135. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE . Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 1977; 34: 247–265. · DOI · Paper page
  136. Cheetham SC, Crompton MR, Katona CLE, Horton RW . Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res 1988; 443: 272–280. · DOI
  137. Cross JA, Cheetham SC, Crompton MR, Katona CL, Horton RW . Brain GABAB binding sites in depressed suicide victims. Psychiatry Res 1988; 26: 119–129. · DOI
  138. Arranz B, Cowburn R, Eriksson A, Vestling M, Marcusson J . Gamma-aminobutyric acid-B (GABAB) binding sites in postmortem suicide brains. Neuropsychobiology 1992; 26: 33–36. · DOI
  139. Stocks GM, Cheetham SC, Crompton MR, Katona CL, Horton RW . Benzodiazepine binding sites in amygdala and hippocampus of depressed suicide victims. J Affect Disord 1990; 18: 11–15. · DOI
  140. Sundman I, Allard P, Eriksson A, Marcusson J . GABA uptake sites in frontal cortex from suicide victims and in aging. Neuropsychobiology 1997; 35: 11–15. · DOI
  141. Korpi ER, Kleinman JE, Wyatt RJ . GABA concentrations in forebrain areas of suicide victims. Biol Psychiatry 1988; 23: 109–114. · DOI
  142. Benes FM, Todtenkopf MS, Logiotatos P, Williams M . Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain. J Chem Neuroanat 2000; 20: 259–269. · DOI
  143. Guidotti A, Auta J, Davis JM, DiGiorgi Gerevini V, Dwivedi Y, Grayson DR et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2000; 57: 1061–1069. · DOI · Paper page
  144. Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive, disorder, bipolar disorder and schizophrenia. Biol Psychiatry 2002; 51: 377–386. · DOI
  145. Honig A, Bartlett JR, Bouras N, Bridges PK . Amino acid levels in depression: a preliminary investigation. J Psychiatric Res 1988; 22: 159–164. · DOI
  146. Northoff G, Steinke R, Czcervenka C, Krause R, Ulrich S, Danos P et al. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J Neurol Neurosurg Psychiatry 1999; 67: 445–450. · DOI
  147. Sanacora G, Mason GF, Rothman DL, Krystal JH . Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002; 159: 663–665. · DOI · Paper page
  148. Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W et al. Cortical γ-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder. Arch Gen Psychiatry 2002; 59: 851–858. · DOI
  149. Soares JC, Mann JJ . The anatomy of mood disorders−review of structural neuroimaging studies. Biol Psychiatry 1997; 41: 86–106. · DOI
  150. Brambilla P, Barale F, Caverzasi E, Soares JC . Anatomical MRI findings in mood and anxiety disorders. Epidemiol Psychiatr Soc 2002; 11: 88–99. · DOI
  151. Gamse R, Vaccaro DE, Gamse G, DiPace M, Fox TO, Leeman SE . Release of immunoreactive somatostatin from hypothalamic cells in culture: inhibition by gamma-aminobutyric acid. Proc Natl Acad Sci USA 1980; 77: 5552–5556. · DOI
  152. Racagni G, Apud JA, Civati C, Cocchi D, Casanueva F, Locatelli V et al. Neurochemical aspects of GABA and glutamate in the hypothalamo-pituitary system. Adv Biochem Psychopharmacol 1981; 26: 261–271.
  153. Koulu M, Lammintausta R, Dahlstrom S . Stimulatory effect of acute baclofen administration on human growth hormone secretion. J Clin Endocrinol Metab 1979; 48: 1038–1040. · DOI
  154. Shiah I-S, Yatham LN, Lam R, Tam EM, Zis PA . Growth hormone response to baclofen in patients with mania: a pilot study. Psychopharmacology 1999; 147: 280–284. · DOI
  155. Shiah I-S, Robertson HA, Lam R, Yatham LN, Tam EM, Zis PA . Growth hormone response to baclofen in patients with seasonal affective disorder: effects of light therapy. Psychoneuroendocrinology 1999; 24: 143–153. · DOI
  156. Marchesi C, Chiodera P, De Ferri A, De Risio C, Dasso L, Menozzi P et al. Reduction of GH response to the GABA-B agonist baclofen in patients with major depression. Psychoneuroendocrinology 1991; 16: 475–479. · DOI
  157. O'Flynn K, Dinan TG . Baclofen-induced growth hormone release in major depression: relationship to dexamethasone suppression test result. Am J Psychiatry 1993; 150: 1728–1730. · DOI
  158. Monteleone P, Maj M, Iovino M, Steardo L . GABA, depression and the mechanism of action of antidepressant drugs: a neuroendocrine approach. J Affect Disord 1990; 20: 1–5. · DOI
  159. Davis LL, Trivedi M, Choate A, Kramer GL, Petty F . Growth hormone response to the GABAB agonist baclofen in major depressive disorder. Psychoneuroendocrinology 1997; 22: 129–140. · DOI
  160. Heninger C, Saito N, Tallman JF, Garrett KM, Vitek MP, Duman RS et al. Effects of continuous diazepam administration on GABAA subunit mRNA in rat brain. J Mol Neurosci 1990; 2: 101–107. · DOI
  161. Kang I, Miller LG . Decreased GABAA receptor subunit mRNA concentrations following chronic lorazepam administration. Br J Pharmacol 1991; 103: 1285–1287. · DOI
  162. Primus RJ, Gallager DW . GABAA receptor subunit mRNA levels are differentially influenced by chronic FG 7142 and diazepam exposure. Eur J Pharmacol 1992; 226: 21–28. · DOI
  163. Holt RA, Bateson AN, Martin IL . Chronic treatment with diazepam or abecarnil differently affects the expression of GABAA receptor subunit mRNAs in the rat cortex. Neuropharmacology 1996; 35: 1457–1463. · DOI
  164. Tanay VA, Glencorse TA, Greenshaw AJ, Baker GB, Bateson AN . Chronic administration of antipanic drugs alters rat brainstem GABAA receptor subunit mRNA levels. Neuropharmacology 1996; 35: 1475–1482. · DOI
  165. Wang J-F, Sun X, Chen B, Young LT . Lamotrigine increases gene expression of GABAA receptor β3 subunit in primary cultured rat hippocampus cells. Neuropsychopharmacology 2002; 26: 415–421. · DOI
  166. Lloyd KG, Thuret F, Pilc A . Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther 1985; 235: 191–199.
  167. Motohashi N, Ikawa K, Kariya T . GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders? Eur J Pharmacol 1989; 166: 95–99. · DOI
  168. Motohashi N . GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 571–579. · DOI
  169. Mendlewicz J . Population and family studies in depression and mania. Br J Psychiatry 1988; 1539Suppl 3): 16–25. · DOI
  170. Oruc L, Verheyen GR, Furac I, Ivezic S, Jakovljevic M, Raeymaekers P et al. Positive association between the GABRA5 gene and unipolar recurrent major depression. Neuropsychobiology 1997; 36: 62–64. · DOI
  171. Papadimitriou GN, Dikeos DG, Karadima G, Avramopoulos D, Daskalopoulou EG, Vassilopoulos D et al. Association between the GABA(A) receptor alpha5 subunit gene locus (GABRA5) and bipolar affective disorder. Am J Med Genet 1998; 81: 73–80. · DOI
  172. Massat I, Souery D, Del-Favero J, Van Gestel S, Van Broeckhoven C, Mendlewicz J . GABRA1 receptor polymorphism and unipolar affective disorder: evidence for a protective gene in a European multicenter association study of affective disorders. Eur Neuropsychopharmacol 2001; 11(Suppl 1): 19.
  173. Massat I, Souery D, Del-Favero J, Oruc L, Noethen MM, Blackwood D et al. Excess of allel1 for 3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. Mol Psychiatry 2002; 7: 201–207. · DOI
  174. De Bruyn A, Sourey D, Mendelbaum K, Mendlewicz J, Van Broeckhoven C . A linkage study between bipolar disorder and genes involved in dopaminergic and GABAergic neurotransmission. Psychiatr Genet 1996; 6: 67–73. · DOI
  175. Ewald H, Mors O, Flint T, Kruse TA . Linkage analysis between manic-depressive illness and the region on chromosome 15q involved in Prader-Willi syndrome, including two GABA A receptor subtype genes. Human Hered 1994; 44: 287–294. · DOI
  176. Walsh C, Hicks A, Sham P . GABAA receptor subunit genes as candidate genes for bipolar affective disorder: an association analysis. Psychiatr Genet 1992; 2: 239–247. · DOI
  177. Puertollano R, Visedo G, Saiz-Ruiz J, Llinares C, Fernandez-Piqueras J . Lack of association between manic-depressive illness and a highly polymorphic marker from GABRA3 gene. Am J Med Genet 1995; 60: 434–435. · DOI
  178. Duffy A, Turecki G, Grof P, Cavazzoni P, Grof E, Joober R et al. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J Psychiatry Neurosci 2000; 25: 353–358.
  179. Coon H, Hicks AA, Bailey ME, Hoff M, Holik J, Harvey RJ et al. Analysis of GABAA receptor subunit genes in multiplex pedigrees with manic depression. Psychiatr Genet 1994; 4: 185–191. · DOI
  180. Papadimitriou GN, Dikeos DG, Karadima G, Avramopoulos D, Daskalopoulou EG, Stefanis CN . GABA-A receptor β3 and α5 subunit gene cluster on chromosome 15q11−q13 and bipolar disorder: a genetic association study. Am J Med Genetics 2001; 105: 317–320. · DOI
  181. Oruc L, Furac I, Croux C, Jakovljevic M, Kracun I, Folnegovic V et al. Association study between bipolar disorder and candidate genes involved in dopamine−serotonin metabolism and GABAergic neurotransmission: a preliminary report. Psychiatr Genet 1996; 6: 213–217. · DOI
  182. Puertollano R, Visedo G, Zapata C, Fernandez-Piqueras J . A study of genetic association between manic-depressive illness and a highly polymorphic marker from the GABRβ-1 gene. Am J Med Gen 1997; 74: 342–344. · DOI
  183. Bernasconi R . The GABA hypothesis of affective illness: influence of clinically effective antimanic drugs on GABA turnover. In: Emrich HD, Aldenhoff HD, Lux HD (eds). Excerpta Medica. Amsterdam, 1982, pp. 183–191.
  184. Loscher W . Valproate enhances GABA turnover in the substantia nigra. Brain Res 1989; 501: 198–203. · DOI
  185. Cunningham MO, Jones RS . The anticonvulsant lamotrigine decreases spontaneous gluatamate release but increases spontaneous GABA release in the rat enthorinal cortex in vitro. Neuropharmacology 2000; 39: 2139–2146. · DOI
  186. Hassel B, Tauboll E, Gjerstad L . Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels. Epilepsy Res 2001; 43: 153–163. · DOI
  187. Otero Losada ME, Rubio MC . Acute and chronic effects of lithium chloride on GABA-ergic function in the rat corpus striatum and frontal cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol 1986; 332: 169–172. · DOI
  188. Ahluwalia P, Grewaal DS, Singhal RL . Brain GABAergic and dopaminergic systems following lithium treatment and withdrawal. Prog Neuropsychopharmacol 1981; 5: 527–530. · DOI
  189. Gottesfeld Z . Effect of lithium and other alkali metals on brain chemistry and behavior. I. Glutamic acid and GABA in brain regions. Psychopharmacologia 1976; 45: 239–242. · DOI
  190. Weiss S, Kemp DE, Bauce L, Tse FW . Kainate receptors coupled to the evoked release of [3H]-gamma-aminobutyric acid from striatal neurons in primary culture: potentiation by lithium ions. Mol Pharmacol 1990; 38: 229–236.
  191. Maggi A, Enna SJ . Regional alterations in rat brain neurotransmitter systems following chronic lithium treatment. J Neurochem 1980; 34: 888–892. · DOI
  192. Vargas C, Tannhauser M, Barros HM . Dissimilar effects of lithium and valproic acid on GABA and glutamine concentrations in rat cerebrospinal fluid. Gen Pharmacol 1998; 30: 601–604. · DOI
  193. Iadarola MJ, Raines A, Gale K . Differential effects of n-dipropylacetate and amino-oxyacetic acid on gamma-aminobutyric acid levels in discrete areas of rat brain. J Neurochem 1979; 33: 1119–1123. · DOI
  194. Loscher W, Vetter M . In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Correlation to pharmacological activities. Biochem Pharmacol 1985; 34: 1747–1756. · DOI
  195. Loscher W, Horstermann D . Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn Schmiedebergs Arch Pharmacol 1994; 349: 270–278. · DOI
  196. Gram L, Larsson OM, Johnsen AH, Schousboe A . Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons. Epilepsy Res 1988; 2: 87–95. · DOI
  197. Phillips NI, Fowler LJ . The effects of sodium valproate on gamma-aminobutyrate metabolism and behaviour in naive and ethanolamine-O-sulphate pretreated rats and mice. Biochem Pharmacol 1982; 31: 2257–2261. · DOI
  198. Macdonald RL, Bergey GK . Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurons. Brain Res 1979; 170: 558–562. · DOI
  199. Loscher W . Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA. J Neurochem 1980; 34: 1603–1608. · DOI
  200. Larsson OM, Gram L, Schousboe I, Schousboe A . Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes. Neuropharmacology 1986; 25: 617–625. · DOI

200 of 277 shown

Cited by

Metadata

Authors
Brambilla, P., Perez, J., Barale, F., Schettini, G., & Soares, J. C.
Venue
Molecular Psychiatry
Publisher
Springer Science and Business Media LLC
Published
2003-07-30
Volume
8
Issue
8
Pages
721-737
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
DOI
10.1038/sj.mp.4001362
OpenAlex
W2142695282
Cited by
553
References
8
FWCI
11.57
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.